Axsome Therapeutics Inc (AXSM)
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders in the United States. Its marketed portfolio includes Auvelity for major depressive disorder in adults, Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine with or without aura. The company is also advancing several clinical-stage programs, including AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-12 for narcolepsy, AXS-14 for fibromyalgia and related conditions, and solriamfetol in additional indications such as attention deficit hyperactivity disorder, major depressive disorder, binge eating, and shift work disorder-related sleepiness. Axsome also has a research collaboration with Duke University evaluating AXS-05 in smoking cessation. Founded in 2012, the company is based in New York, New York.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AXSM
|
$243.52
|
7.9% Upside
|
Fair
|
$281.80
|
24.9% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-61.7x
|
213.0x
|
16.4x
|
11.406 B
|
11.541 B
|
1.9%
|
84.6%
|
8.0
|
—
|
37.7%
|
